Skystar Bio-Pharmaceutical Begins Trading on NASDAQ Capital Market

XI’AN, CHINA--(Marketwire - June 26, 2009) - Skystar Bio-Pharmaceutical Co., Ltd. (NASDAQ: SKBI) (“Skystar”), a leading China-based producer and distributor of veterinary medicines, vaccines, microorganisms and feed additives, announced that its common stock will begin trading on the NASDAQ Capital Market under the symbol SKBI, effective at the open of trading today, June 26, 2009.

Weibing Lu, Chairman and Chief Executive Officer of Skystar, stated, “Our move to NASDAQ is a major milestone achievement for Skystar following the substantial growth that we have delivered in revenue, earnings, production capacity and product development. We believe that the NASDAQ Capital Market provides excellent exposure for companies such as ours in emerging markets. This move underscores our commitment to generating long-term value for our shareholders.”

Most recently, the company’s common stock traded on the OTC Bulletin Board under the symbol SKBO.

About Skystar Bio-Pharmaceutical Co.

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, microorganisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

To be added to the Company’s email distribution for future news releases, please send your request to kristen@tpg-ir.com.

Forward-looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.